Latest news with #AndrewBerens
Business Insider
3 days ago
- Business
- Business Insider
Arvinas downgraded to Market Perform from Outperform at Leerink
Leerink analyst Andrew Berens downgraded Arvinas (ARVN) to Market Perform from Outperform with a price target of $9, down from $10, after the company presented full results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant in second-line HR+/HER2- metastatic breast cancer patients. The firm says that while the full presentation demonstrates the drug is active in patients with ESR1 mutations and likely approvable, it is not convinced vepdeg is best-in-class. Further, a number of key uncertainties in the rapidly evolving treatment paradigm for ESR1m breast cancer landscape have emerged, the analyst tells investors in a research note. Leerink 'gradually tempered the ESR1m rate in second-line from 30% to 15% to reflect potential impact from the SERENA-6 data, as well as ongoing first-line oral SERD trials, lowering its assumed worldwide peak vepdeg sales to $416M from $576M.
Business Insider
24-05-2025
- Business
- Business Insider
AstraZeneca (AZN) Receives a Buy from Leerink Partners
In a report released on May 21, Andrew Berens from Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report). The company's shares closed yesterday at $70.41. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Berens covers the Healthcare sector, focusing on stocks such as Incyte, Arvinas Holding Company, and AstraZeneca. According to TipRanks, Berens has an average return of -6.7% and a 36.16% success rate on recommended stocks. Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $87.34. The company has a one-year high of $87.68 and a one-year low of $61.24. Currently, AstraZeneca has an average volume of 6.03M.
